Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Thoracic 1

Conditions

Respiratory Tract Diseases 1Neoplasms 1Meningeal Carcinomatosis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Temozolomide 166Magnetic Resonance Spectroscopy 131Radiotherapy 97Specimen Handling 81Radiosurgery 61Cyclophosphamide 56pembrolizumab 52Bevacizumab 52Radiation 48Nivolumab 48Carboplatin 36Biopsy 33Irinotecan 29Etoposide 25Vincristine 24Lomustine 24Topotecan 23Ipilimumab 23Blood Specimen Collection 23Cisplatin 22dinutuximab 21fludarabine 19Surgical Procedures, Operative 19Radiotherapy, Intensity-Modulated 19X-Rays 18abemaciclib 16Mental Status and Dementia Tests 16Granulocyte-Macrophage Colony-Stimulating Factor 16Pemetrexed 15atezolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
AZD3759 × CNS × 1 year × Clear all
NCT07361705 2026-01-23

Zorifertinib With Osimertinib for NSCLC With Meningeal Progression

Alpha Biopharma (Jiangsu) Co., Ltd.

Phase 1 Not yet recruiting
42 enrolled
CNS

Meningeal Carcinomatosis

NCT03653546 2025-09-10

BM

Alpha Biopharma (Jiangsu) Co., Ltd.

Phase 2/3 Completed
492 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡